Medincell company information, Employees & Contact Information

Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York) MarketScreener

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder Sahm

First subcutaneous risperidone: FDA approves UZEDY for adult Bipolar I; monthly 50/75/100 mg Stock Titan

Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the PharmiWeb.com

Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge simplywall.st

Medincell wins milestone from Teva on back of SOLARIS trial The Pharma Letter

Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241 BioSpace

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder Koreabizwire

In Vitro and In Vivo Hydrolytic Degradation Behaviors of a Drug-Delivery System Based on the Blend of PEG and PLA Copolymers ACS Publications

FDA approves Teva and Medincell’s bipolar I disorder treatment Pharmaceutical Technology

MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission Business Wire

Medincell and iM4TB initiate development of a long-acting injectable version of macozinone, a promising investigational TB treatment European AIDS Treatment Group

Medincell, AbbVie partner on long-term injectable therapies drugdiscoverytrends.com

Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI) sharewise.com

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Business Wire

AbbVie links up with Medincell for $2B injectables deal FirstWord Pharma

Medincell and AbbVie enter injectable therapy development deal Pharmaceutical Technology

Medincell, AbbVie link up in long-acting injectable development pact worth up to $1.9B Fierce Pharma

Teva, MedinCell receive FDA approval for Uzedy to treat schizophrenia Pharmaceutical Technology

Medincell, Abbvie Enter Development and Commercialization Pact Contract Pharma

Corbion enables drug delivery innovation behind new FDA-approved product to treat schizophrenia GlobeNewswire

Teva-partnered MedinCell bags $42M loan for long-acting injectable R&D Fierce Pharma

FDA Accepts Supplemental New Drug Application for Teva, Medincell’s Uzedy for Bipolar I Disorder Pharmaceutical Executive

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia Yahoo Finance

Teva, MedinCell win FDA approval for slow-release schizophrenia drug Uzedy Fierce Pharma

MedinCell reports positive data from Covid-19 prevention medicine trial Clinical Trials Arena

Teva, Medincell's schizophrenia drug succeeds in late-stage study Reuters

Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial Clinical Trials Arena

Uzedy partners Teva and MedinCell's latest long-acting schizophrenia candidate notches phase 3 win Fierce Pharma

How strong is MedinCell S.A. (MEB) stock earnings growth - 2025 Market Trends & Low Risk High Win Rate Stock Picks newser.com

A Closer Look at MedinCell (ENXTPA:MEDCL) Valuation Following FDA Approval for UZEDY in Bipolar I Disorder simplywall.st

MedinCell Enters Into a Technology Agreement for Long-Acting Injectable Products PR Newswire

MedinCell advances long-acting COVID-19 injectable program Fierce Pharma

BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery kinetics modulation ScienceDirect.com

Teva and MedinCell report positive data from schizophrenia trial Clinical Trials Arena

Why MedinCell S.A. (MEB) stock remains stable - 2025 Sector Review & High Accuracy Swing Entry Alerts Trung tâm Dự báo KTTV quốc gia

Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris BioSpace

Medincell Says Phase 3 Data Shows No PDSS In Olanzapine LAI TradingView

Why MedinCell S.A. (MEB) stock remains stable - July 2025 PostEarnings & Risk Managed Trade Strategies Trung tâm Dự báo KTTV quốc gia

AbbVie injectables deal with French biotech could be worth $1.9B Crain's Chicago Business

MedinCell Granted €17M to Develop Cheap Long-Acting Contraception Labiotech.eu

Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3 Fierce Pharma

Medincell at fresh record high FDA expands indication for schizophrenia treatment TradingView

Phase 3 SOLARIS Trial Demonstrates Potential of TEV-‘749 in Schizophrenia Psychiatric Times

Slow-Release Drug Biotech Medincell's IPO Raises €30M Labiotech.eu

European Insider-Owned Growth Stocks To Watch In October 2025 simplywall.st

Teva receives CRL for reformulated schizophrenia drug developed with French biotech Endpoints News

MedinCell’s partner AIC registers trial for drug for total knee replacement pain Labiotech.eu

Medincell: FDA approves expanded indication for Uzedy MarketScreener

MedinCell and Corbion Form CM Biomaterials Technology Networks

FDA delays approval for Teva schizophrenia drug Globes - Israel Business News

FDA approves innovative Teva schizophrenia drug Globes - Israel Business News

FDA approves innovative Teva schizophrenia drug גלובס